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INTRODUCTION 
The publication of the Calman-Hine Report (Department of
Health, 1995) on the commissioning of cancer services has
focused attention on the organisation of services for gynaecolog-
ical cancer. Gynaecological cancers are, by definition, rare cancers
and it has been advocated that the centralisation of services will
lead to improved quality of care. This assertion has been supported
by several recent publications (Jackson et al, 1997), particularly
relating to ovarian cancer (Junoer et al, 1994; Kehoe et al, 1994).
Ovarian cancer, the commonest gynaecological cancer, has a poor
outcome, with a five-year survival of 30–40% (Nguyen et al,
1993). This has been attributed, in part, to late presentation of
disease, with the majority of cases having extra-ovarian spread at
diagnosis (Nguyen et al, 1996). The principles employed in the
treatment of epithelial ovarian cancer are consensus rather than
research-based and involve surgical resection of the disease,
followed by chemotherapy. Prescribed optimal cytoreductive
surgery, which involves reducing the disease to less than 2 cm, can
be particularly challenging in cases of advanced ovarian cancer.
Previous publications have demonstrated that Gynaecological
Oncological surgeons achieve better outcomes in terms of smaller
residual disease after surgery (Junor et al, 1994) and improved
survival (Kehoe et al, 1994; Junor et al, 1999) than their general
gynaecological or surgical colleagues. 
The South West region of England is a large geographical
region, stretching 220 miles from Gloucester in the north of the
region to Penzance at its southernmost tip. The region is served by
five cancer centres: Three Counties Centre to the north of the
region which serves Cheltenham, Gloucester and Hereford hospi-
tals; Avon and Somerset cancer centre based in Bristol; Exeter and
Plymouth cancer centres in the south west of the region and Dorset
in the south east. Wiltshire became a part of Avon and Somerset
cancer centre at the end of 1998 (See Appendix 1). The current
organisation of gynaecological cancer services in the South West
of England is similar to the rest of the country. The regional cancer
centre receives primary referral from its catchment population and
tertiary referrals of more complicated or relapsed cases from asso-
ciated cancer units and district hospitals. Most ovarian cancer
cases receive their primary treatment in their local hospital and are
referred centrally if they require further surgery or chemotherapy.
This arrangement may change in the near future following the
implementation of the recently published National Health Service
Executive document ‘Improving Outcomes in Gynaecological
Cancer’ (NHS Executive, 1999). In this document, it has been
advocated that all women with ovarian cancer be referred to recog-
nised cancer centres so that they can receive optimal management
for their disease, with multidisciplinary input into the planning
of their management, expert surgery and chemotherapy from
dedicated gynaecological surgeons and oncologists. 
There are particular challenges to developing this model of care
in a region with a widespread rural population. We therefore
decided to study the surgical management of epithelial ovarian
cancer in the South West of England in the two years 1997–1998
The surgical management of women with ovarian
cancer in the south west of England 
A Olaitan1, J Weeks2, A Mocroft3, J Smith1, K Howe1, and J Murdoch1
1Department of Gynaecological Oncology, St Michael’s Hospital, Southwell Street, Bristol, BS2, 8EG; 2Regional Cancer Organisation, Avon Health Authority;
3Department of Primary Care & Population Sciences, Royal Free & University College Medical School, Royal Free Campus, Rowland Hill Street, London 
NW3 2PF, UK 
Summary The surgical management of epithelial ovarian cancer in the South West of England was studied in the two years 1997–1998 in
order to determine the factors that influence the outcome of surgery and to provide a baseline from which to assess the effect of centralisation
of cancer services. All hospitals in the South West region of England participating in the Regional Cancer Organisation’s longitudinal study of
outcomes in gynaecological malignancies are included. Six hundred and eighty-two patients with epithelial ovarian cancer were registered
with the RCO in the two-year study period. Five hundred and ninety-five women were offered primary cytoreductive surgery of which 438 were
said to be optimally cytoreduced. Applying multivariate models to analyse the outcome of surgery, older patients (OR = 0.82 per 5-year
increase in age, P = 0.0003), patients treated in hospitals managing fewer than ten cases of ovarian cancer per year (OR = 1.92, P = 0.02)
and patients with FIGO stage 3 (OR = 0.02, P < 0.0001) or 4 (OR = 0.002, P < 0.0001) disease were less likely to be optimally cytoreduced.
Gynaecological oncologists were 2.06 times more likely to attain optimal cytoreduction when compared to general gynaecologists and this
was statistically significant (P = 0.01). The results from this study support the argument that limiting surgery for ovarian malignancy to
specialised surgeons improves the extent of cytoreductive surgery. © 2001 Cancer Research Campaign http://www.bjcancer.com
Keywords: ovarian cancer; surgery; cytoreduction; gynaecological oncologist 
1824
Received 4 September 2000 
Revised 17 September 2001 
Accepted 3 October 2001 
Correspondence to: A Olaitan 
British Journal of Cancer (2001) 85(12), 1824–1830
© 2001 Cancer Research Campaign
doi: 10.1054/ bjoc.2001.2196, available online at http://www.idealibrary.com on 
On behalf of: South and West Tumour Panel for Gynaecological Cancer R Anderson,
P Bliss, I Boyd, T Clarke, R Counsell, J Cullimore, F Daniel, A Falconer, E Gilby,
J Giles, J Graham, L Hirschowitz, A Hong, N Johnson, V Laurence, R Marshall,
JB Murdoch, J Orford, JN Renninson, J Richardson, G Swingler 
http://www.bjcancer.comSurgical management of ovarian cancer 1825
British Journal of Cancer (2001) 85(12), 1824–1830 © 2001 Cancer Research Campaign
prior to the re-organisation of gynaecological cancer services,
looking particularly at factors influencing the completeness of
surgery at each stage of disease. This study, as well as providing a
base-line against which future performance can be measured,
enables us to estimate the increase in work load and the resource
implications for the regional cancer centre if centralisation of
ovarian cancer management is fully implemented. 
MATERIALS AND METHODS 
The South and West Regional Cancer Organisation (RCO)
Gynaecology Tumour Panel is constituted of a multidisciplinary
team of experts involved in the management of gynaecological
malignancies. In 1997, the RCO initiated a prospective longitu-
dinal study of the management of gynaecological cancer to estab-
lish current patterns of care and facilitate development of services
in the region (Jackson et al, 1997). A one-page minimum data-set
for each major gynaecological cancer site was designed (Figure 1).
After obtaining approval from all units managing gynaecological
malignancies, copies of the minimum data set pro forma were
circulated along with guidance notes that included outlines of
American Society of Anesthesiologists (ASA) grading, FIGO
staging, and histopathology information required. Treatment policies
detailing accepted pre-operative and operative management of
epithelial ovarian cancer were produced and circulated by the RCO
to all participating hospitals (Appendix 1). To ensure uniform
histopathological reporting, the RCO also circulated guidelines for
participating histopathologists (Appendix 2). The clinician managing
the case is responsible for filling the form and for returning a copy to
the RCO. The data are then entered on a central Microsoft Access™
database managed by one of the co-authors (JW). Complete data on
surgical procedures are available for 1997 and 1998. 
Data for all ovarian cancer cases registered with the RCO from
January 1997 to December 1998 were obtained from the RCO data-
base. Central validation by the RCO had previously confirmed
registration rates of close to 100% for all hospitals participating in
1997 (Regional Cancer Organisation, 1999). To ascertain complete-
ness of the data and to identify outstanding cases not registered with
the RCO, the histopathology departments of participating hospitals
were approached for lists of patients with a histological diagnosis
of ovarian cancer during the study period. Any cases thus identi-
fied were checked with the appropriate clinician, yielding some
additional registrations. 
The total number and FIGO stage of epithelial ovarian cancer
cases managed by each contributing hospital per year was calcu-
lated. The accuracy of the FIGO stage was examined by comparing
the ascribed FIGO stage with the clinico-pathological data supplied
on the RCO form. These details were checked against the specialisa-
tion of the surgeon responsible for the case. Cases were re-staged by
one of the authors (AO) if there was a mismatch between ascribed
FIGO stage and the clinico-pathological data available. Where no
FIGO stage was stated, patients were allocated a stage where there
was sufficient staging information supplied on the RCO form.
Sub-stages were ascribed or confirmed where this information was
available. Cases were left without a clinical stage where there was
insufficient clinico-pathological information available. Cases were
also left unstaged where there was insufficient information to
confirm the original FIGO stage allocated. The amended FIGO
staging was applied in all subsequent analysis. 
All cases undergoing primary surgery were classified according
to extent of surgery per stage of disease. Patients with less than 2
cm residual disease at the end of surgery were classified as
receiving optimal cytoreductive surgery while those with greater
than 2 cm residual disease were classified as receiving sub-
optimal surgery. 
Statistical methods 
Univariate and multivariate logistic regression analyses were
applied to determine the factors related to both the decision to
offer surgery and on the outcome of surgery. The factors investi-
gated included age, ASA grade, stage of disease, grade and
specialisation of surgeon, consultant supervision, and the number
of ovarian cancer operations per contributing hospital per year
(classified as 10 or fewer cases of ovarian cancer per year or
greater than 10 cases per year). 
The operating surgeons were classified as general surgeons,
general gynaecologists and gynaecological oncologists according
to the information supplied on the RCO form. A gynaecological
oncologist was defined as an RCOG-recognised sub-speciality
trained individual (of which there is one in the region) or the lead
Consultant for gynaecological oncology within a cancer centre. In
addition, lead clinicians for gynaecological cancer within teaching
or district hospitals with a large caseload (15 or more cases of
ovarian cancer per surgeon per year) were included in this defini-
tion, giving a total of nine gynaecological oncologists within the
region. 
RESULTS 
A total of 820 ovarian cancer cases were registered with the RCO in
the study period 1997–1998 from 20 NHS and eight private hospi-
tals. Of these, 36 were non-epithelial tumours. Non-epithelial
cancers are not considered in this study and have been excluded
from all further analyses. A further eight cases were excluded as
they had secondary ovarian tumours from a non-gynaecological
primary. Other exclusions included 15 patients with sychronous
primaries, the second tumour being non-ovarian and 21 patients
who were registered with recurrent ovarian cancer. Of the 740
remaining patients, 58 were registered by hospitals outside the
south west region where we were unable to crosscheck the number
of ovarian cancer cases with the histopathology department. These
patients were therefore also excluded, leaving a total of 682 cases
registered with the RCO with a verified diagnosis of primary
epithelial ovarian cancer. This number included 129 cases of
borderline epithelial tumours. The median age of these patients was
62 years (range 18–94). Figure 2 illustrates the total number of
cases registered by each hospital per year. Some hospitals only
started to register gynaecological cancer cases with the RCO in
1998 and this is reflected in the relatively small number of cases
registered. A total of 94 surgeons, including seven general surgeons
and one breast surgeon managed these cases. The median number
of cases managed per surgeon over the two-year study period was
four (range 1–72). Figure 3 illustrates the number of ovarian cancer
cases undertaken by the lead clinician for gynaecological cancer
services in each contributing hospital in the two year study period.
The Dorset hospitals (see Appendix 1) are not included in this
figure as they only started to register cases with the RCO in 1998. 
Eighty-nine patients were re-staged because the clinico-
pathological information given on the RCO form did not match the
FIGO stage ascribed while there were 132 cases where there was
insufficient data to confirm or assign a stage, making a total of 2211826 A Olaitan et al
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Figure 1 Regional Cancer Organisation Registration Pro forma (32.5%) unsatisfactorily staged cases. Table 1 describes the re-
staging action taken classified according to the specialisation of
the surgeon managing the case. Staging was accurate in 81.6% of
cases managed by gynaecological oncologists, 62.8% of cases
managed by general gynaecologists and 32.1% of cases managed
by general surgeons. 
Five hundred and ninety-five patients (87.2%) were managed
surgically while 69 (9.9%) had laparoscopy and biopsy only. In
438 (81.2%) of the surgical cases, the Consultant was the primary
surgeon. In 14 cases, the grade of the primary surgeon was not
indicated. The remaining 98 were operated on by surgeons in non-
Consultant grades, specialist registrars in the majority of cases.
Sixty-two (63.0%) of these procedures were undertaken under
Consultant supervision. In all 545 (92%) of procedures were
performed by consultants or under consultant supervision. The
surgeons undertaking ovarian cancer surgery without supervision
included specialist registrars in year 3 (three cases), year 4 (three
cases), year 5 (12 cases) and nine cases undertaken by a variety of
non-consultant grade surgeons including staff grade doctors. 
The amended FIGO stage at presentation of patients who under-
went definitive surgery and those who did not is described in Table 2.
Table 3 shows the ASA grade of patients undergoing surgery
compared with those managed conservatively. 
Four hundred and thirty-eight (73.8%) were described as having
less than 2 cm of residual disease after surgery while 119 women
had more than 2 cm of residual disease. Table 4 describes the
FIGO stage at presentation of these patients and the cytoreductive
rates tabulated against the operating surgeon’s specialisation. 
Applying univariate analysis to determine the factors influ-
encing the decision to undertake surgery revealed that patients
were less likely to be offered surgery if they were of older age
(odds ratio (OR) per 5-year increase in age = 0.89, P = 0.005), in
ASA grade 3 or 4 (OR 0.30, P < 0.0001) and had FIGO stage 4
disease at presentation (OR=0.10, P < 0.0001). In multivariate
analyses, age was no longer significant, but patients in ASA grade 3
or 4 remained significantly less likely to be offered surgery (OR 0.3,
P < 0.0001), as were patients in FIGO stage 4 (OR 0.10, 
P = 0.0001). In addition, in multivariate analyses, there was no
significant difference in the likelihood of undergoing surgery by the
Surgical management of ovarian cancer 1827
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Figure 2 Number of ovarian cancer cases managed per hospital
1997–1998
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Figure 3 Number of ovarian cancer cases/lead clinician in two-year study
period 
Table 1 Amended stage of ovarian cancer classified according to specialisation of responsible surgeon 
Specialisation No Down- Up- Staged Up-substage Down-substage No  Stage Total
Change staged staged
Gynae 243 27 10 19 4 5 79 387 (56.7) 
Gynae-Onc 199 5 5 5 0 1 29 244 (35.8) 
Surgeon 9 2 1 0 0 0 16 28 (4.1) 
Not Stated 10 3 1 1 0 0 8 23 (3.4) 
Total 461 37 17 25 4 6 132 682 
(%) (67.5) (5.4) (2.5) (3.7) (0.6) (0.9) (19.4) (100) 
Table 2 FIGO stage of ovarian cancer at presentation comparing patients
who underwent primary surgery with those who did not 
FIGO  Total no. Total no. Total no.
Stage of cases (%) with surgery (%) no surgery (%) 
I 156 (22.9) 155 (22.7) 1 (1.2) 
II 51 (07.5) 51 (7.4) 0 (0.0) 
III 318 (46.6) 272 (39.9) 46 (6.7) 
IV 24 (3.5) 13 (1.9) 11 (1.6) 
Unstated 133 (19.5) 104 (15.2) 29 (4.3) 
Total 682 (100) 595 (87.2) 87 (12.8) 
Table 3 ASA grades of patients undergoing surgery compared with those
who had no surgery 
ASA  Total no. Total no with  Total no with
grade of cases (%)  surgery (%) no surgery (%) 
1 293 (43.0) 277 (40.6) 16 (2.3) 
2 204 (29.9) 179 (26.2) 25 (3.7) 
3 104 (15.2) 78 (11.4) 26 (3.8) 
4 8 (1.2) 4 (0.6) 4 (0.6) 
not stated 73 (10.7) 57 (8.4) 16 (2.3) 
Total 682 (100) 595 (87.2) 87 (12.8) 1828 A Olaitan et al
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caseload of the hospital (OR = 1.01, P = 0.97) or by the specialisa-
tion of the surgeon (OR = 1.33, P = 0.32) when comparing gynae-
cological oncologists with general gynaecologists. 
These factors also had an effect on the outcome of surgery. In
multivariate models, older patients were less likely to be optimally
cytoreduced (OR = 0.82 per 5-year increase in age, P = 0.0003).
Similarly patients with FIGO stage 3 (OR = 0.02, P < 0.0001) or 4
(OR = 0.002, P < 0.0001) disease were less likely to be optimally
cytoreduced. Patients treated in hospitals managing fewer than
10 cases per year were less likely to be optimally cytoreduced
(OR = 1.92,  P = 0.02) compared to those treated in hospitals
managing 10 or more cases per year. ASA grade appeared to have
no effect on the extent of surgery. Gynaecological oncologists
were significantly more likely to attain optimal cytoreduction
when compared to general gynaecologists (OR = 2.06, P = 0.01)
while general surgeons were less likely to attain optimal cytore-
duction although this difference was not statistically significant
(OR = 0.30, P = 0.18). 
DISCUSSION 
The peculiar geography of the South West Region may make
centralisation of gynaecological cancer services particularly chal-
lenging. The large expanse of rural and sparsely populated land
means that there are several hospitals serving relatively small
populations. Consequently, the majority of surgeons participating
in this survey managed fewer than ten cases of ovarian cancer per
year. The median number of cases per surgeon was four and over
half of the lead surgeons for cancer services were operating on
fewer than ten cases of ovarian cancer per year. The need to main-
tain a critical volume of work in order to sustain surgical expertise
has been extensively discussed (Department of Health 1995;
Jackson et al, 1997). Trimbos et al (2000), using surgery for
cervical cancer as a model, demonstrated that there is a long
learning curve associated with surgery for gynaecological cancer.
They demonstrated a reduction in operative blood loss and oper-
ating time achieved by the same operating team over a period of
thirteen years. 
Eighty-nine patients (13%) required re-staging due to discrepan-
cies between the ascribed FIGO stage and the clinico-pathological
data supplied on the RCO form. One hundred and thirty-two
patients (19.4%) could not be allocated a stage because there was
insufficient staging data available on the RCO form. The majority
of cases managed by gynaecological oncologists were accurately
staged but this proportion was decreased in general gynaecologists
and more so for general surgeons where, in the majority of cases,
there was insufficient staging information recorded. Accurate
staging is of critical importance as the decision about whether to
recommend adjuvant therapy is based on this. In addition, analyses
of survival data become meaningless if the correct FIGO stage is
not established at the outset. 
Although the same selection criteria for surgery were apparently
applied through all centres, with older, less fit women being less
likely to be offered surgery, hospitals that managed more than ten
cases of ovarian cancer a year achieved better optimal cytoreduc-
tion rates than those managing ten or fewer cases per. In keeping
with previous published reports (Junor et al, 1994; Kehoe et al,
1994), sub-specialist gynaecological oncologists achieved signifi-
cantly better optimal cytoreduction rates than their non-sub-specialist
colleagues although the majority of operations were carried out by
general gynaecologists. The improved cytoreduction rates achieved
by gynaecological oncologists (as defined by this paper) may reflect
their higher case volume. There is only one RCOG-recognised sub-
specialty trained gynaecological oncologist in the region and so the
other ‘gynaecological oncologists’ included in this analysis were
defined by their work-load. The more widespread introduction of
sub-specialty training in gynaecological oncology will, in future,
allow tighter definitions of specialists and consequently, more
specific analyses. 
Although there are no randomised controlled trials analysing the
effect of optimal cytoreductive surgery on median survival, a large
number of retrospective studies have documented a favourable
prognostic effect on median survival (Hogberg et al, 1993; Marsoni
et al, 1990). A meta-analysis of 58 studies showed that maximum
cytoreductive surgery produced a small improvement in median
survival time (Hunter et al, 1992). 
It is of concern that, although this happened infrequently, a
number of junior doctors undertook surgery for ovarian cancer
without supervision. However, the RCO does not routinely collect
data about which cases were undertaken as emergencies and it may
be that some of these cases presented acutely and that there was no
prior suspicion of cancer. Appropriately, the majority of operations
(92%) were undertaken by or supervised by Consultants. 
The main drawback of this analysis is the failure to include data
on chemotherapy. There is a lag phase of up to six months between
surgery and completion of chemotherapy and the data for 1998 are
as yet, incomplete. We would aim to include chemotherapy data in
our subsequent analysis. 
The follow-up period in this study is too short to examine survival,
particularly as chemotherapy data are incomplete. However, previous
publications (Junor et al, 1999) have shown a survival advantage in
patients operated on by gynaecological oncologists over general
Table 4 FIGO stage of patients undergoing optimal cytoreductive surgery classified according to surgeon’s specialisation 
FIGO Gynaecologist  Gynaecological  oncologist Surgeon  Unstated Total 
stage 341 219 20 15 595 
Total < 2 cm > 2 cm Unst < 2 cm >2 cm Unst.  <2 cm >2 cm Unst.  <2 cm >2 cm Unst. 
I 94 1 7 46 0 2 1 0 0 1 0 0 152 
II 23 1 1 20 0 0 1 0 2 4 0 1 53 
III 67 66 7 82 36 6 1 3 1 3 0 1 273 
IV 0 6 2 4 0 0 0 0 0 0 0 0 12 
Unst. 62 1 5 20 0 1 10 1 0 2 0 3 105 
Total 246 75 22 172 36 9 13 4 3 10 0 5 595 
% 71.8 22.0 6.2 77.6 18.3 4.1 65.0 20.0 15.0 66.7 0.0 33.3  100 
Unst = UnstatedSurgical management of ovarian cancer 1829
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gynaecologists or surgeons. Longitudinal follow-up is on-going and
we should be in a position to analyse survival next year with the
advantage of prospectively collected data. 
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APPENDIX 1 Contributing hospitals 
Cancer Centre 1997 Hospital 
NHS 1 Plymouth Derriford  Plymouth 
2  Plymouth Treliske RCH Truro 
3  Exeter Exeter RD & E 
4 Exeter NDDH  Barnstable 
5 Exeter Torbay 
6  3 Counties CGH Cheltenham 
7  3 Counties GRH Gloucester 
8  3 Counties Hereford County Hospital 
9  Avon & Somerset Bath RUH 
10  Avon & Somerset Frenchay Bristol 
11  Avon & Somerset MPH Taunton 
12  Avon & Somerset Southmead Bristol 
13  Avon & Somerset St Michael’s Bristol 
14  Avon & Somerset Weston General 
15  Avon & Somerset Yeovil District Hospital 
16 Wiltshire Salisbury  (Odstock) 
17  Wiltshire Swindon Princess Margaret 
18 Dorset Poole  Hospital 
19  Dorset Royal Bournemouth General 
20  Dorset West Dorset Dorchester 
PRIVATE 
1 Plymouth Duchy  Cornwall 
2 Exeter Mount  Stuart 
3  3 Counties Cotswold Nuffield Royal 
4 3  Counties Winfield 
5  Avon & Somerset Bath Clinic 
6  Avon & Somerset Chesterfield 
7  Avon & Somerset Glen Bristol 
8  Avon & Somerset Somerset Nuffield 1830 A Olaitan et al
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APPENDIX 2 RCO Guidance Notes for Surgeons & Pathologists
SOUTH AND WEST REGIONAL CANCER ORGANISATION 
King Square House, King Square, Bristol BS2 8EE 
HISTOPATHOLOGY GUIDELINES 
1. Cervical carcinoma 
a) Squamous carcinoma—this category includes typical squamous carcinomas showing all grades of differentiation and of both large and
small cell subtypes. The category also includes papillary squamous carcinomas and condylomatous carcinomas. Micro-invasive carci-
nomas of squamous type should also be recorded in this category. Verrucous carcinomas (which are invariably well-differentiated) are
also of squamous type and should be included in this category. However, since the behaviour of these tumours differs from the other
types of squamous carcinoma, in addition to ticking the “squamous” box on the form, please write “verrucous” alongside the box as
well. 
b) Adenocarcinoma—adenocarcinomas of endocervical, endometrial papillary serous, clear cell and enteric types are all included in this
category as is minimal deviation adenocarcinoma. Early invasive adenocarcinoma should also be recorded. 
c) Other—adenosquamous carcinomas, mixed tumours, small cell carcinomas (basaloid, neuroendocrine), undifferentiated carcinoma,
glassy cell carcinoma, adenoid cystic carcinoma and malignant mixed mesodermal (Mullerian) tumours. 
2. Endometrial carcinoma 
a) Usual type—endometrioid adenocarcinomas are deemed to be of “usual type”. This category includes endometrioid adenocarcinomas
with squamous/morular metaplasia, secretory carcinomas, papillary and ciliated cell variants. 
b) High grade type—this category includes papillary serous adenocarcinomas, clear cell, adenosquamous, squamous and undifferentiated
carcinomas. 
c) Other—malignant mixed mesodermal/Mullerian tumours and any other tumours not included in categories a) or b) above. 
3. Ovarian carcinoma 
a) Borderline and invasive epithelial tumours—include serous, mucinous (endocervical and enteric), transitional/Brenner, endometrioid
and clear cell/mesonephroid tumours. Undifferentiated carcinomas are also included in the invasive epithelial group. 
b) Other—this category includes all other ovarian tumours (including carcinomas arising in teratomas). 
4. Vulval carcinoma 
a) Squamous carcinomas—include warty/condylomatous carcinoma, spindle cell squamous carcinomas, scams carcinoma with tumor
giant cells and acantholytic squamous cell carcinoma. 
b) Verrucous carcinoma—is listed separately because it differs in clinical behaviour from typical squamous carcinoma. 
c) Other—basal cell carcinoma, mixed tumours, Paget’s disease, Melanomas, adenocarcinomas arising locally within adnexal or
vestibular glands and any type of carcinoma no listed in a) or b) above. 